{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:52:21Z","timestamp":1778057541620,"version":"3.51.4"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000913","name":"James S. McDonnell Foundation","doi-asserted-by":"publisher","award":["220020560"],"award-info":[{"award-number":["220020560"]}],"id":[{"id":"10.13039\/100000913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["MTM2015-71200-R"],"award-info":[{"award-number":["MTM2015-71200-R"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011698","name":"Junta de Comunidades de Castilla-La Mancha","doi-asserted-by":"publisher","award":["SBPLY\/17\/180501\/000154"],"award-info":[{"award-number":["SBPLY\/17\/180501\/000154"]}],"id":[{"id":"10.13039\/501100011698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000913","name":"James S. McDonnell Foundation","doi-asserted-by":"publisher","award":["220020450"],"award-info":[{"award-number":["220020450"]}],"id":[{"id":"10.13039\/100000913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1006778","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T13:24:16Z","timestamp":1563197056000},"page":"e1006778","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-495X","authenticated-orcid":true,"given":"V\u00edctor M.","family":"P\u00e9rez-Garc\u00eda","sequence":"first","affiliation":[]},{"given":"Luis E.","family":"Ayala-Hern\u00e1ndez","sequence":"additional","affiliation":[]},{"given":"Juan","family":"Belmonte-Beitia","sequence":"additional","affiliation":[]},{"given":"Philippe","family":"Schucht","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-1135","authenticated-orcid":true,"given":"Michael","family":"Murek","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Raabe","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3548-9961","authenticated-orcid":true,"given":"Juan","family":"Sep\u00falveda","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"DN Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jnen\/64.6.479","article-title":"Population-based studies on incidence, survival rates and genetic alterations in astrocytic and oligodendroglial gliomas","volume":"64","author":"H Ohgaki","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"issue":"18","key":"ref3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/jama.2012.12807","article-title":"Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas","volume":"308","author":"AS Jakola","year":"2012","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11060-015-1948-1","article-title":"The role of radiotherapy in the management of patients with diffuse low grade glioma","volume":"125","author":"TC Ryken","year":"2015","journal-title":"J Neurooncol"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1215\/15228517-2008-063","article-title":"Quality of life in low-grade glioma patients receiving temozolomide","volume":"11","author":"R Liu","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jnnp-2014-308136","article-title":"Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide","volume":"86","author":"JAF Koekkoek","year":"2014","journal-title":"J of Neurol, Neurosurg and Psychiatry"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijrobp.2014.11.012","article-title":"Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424","volume":"91","author":"BJ Fisher","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1078-0432.CCR-08-0888","article-title":"Phase II study of protracted daily temozolomide for low-grade gliomas in adults","volume":"15","author":"S Kesari","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"21","key":"ref9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1212\/01.wnl.0000262034.26310.a2","article-title":"Temozolomide for low-grade gliomas: predictive impact of 1p\/19q loss on response and outcome","volume":"68","author":"G Kaloshi","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-014-1538-7","article-title":"Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma","volume":"120","author":"J Jo","year":"2014","journal-title":"J of Neuro-Oncol"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"BG Baumert","year":"2016","journal-title":"Lancet Oncology"},{"issue":"2","key":"ref12","first-page":"242","article-title":"Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide","volume":"19","author":"M Wahl","year":"2017","journal-title":"Neuro-oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrc4029","article-title":"The mathematics of cancer: Integrating quantitative models","volume":"15","author":"PM Altrock","year":"2016","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"ref14","first-page":"423","article-title":"Applied mathematics and nonlinear sciences in the war on cancer","volume":"1","author":"VM P\u00e9rez-Garc\u00eda","year":"2016","journal-title":"App Math Nonlin Sci"},{"issue":"23","key":"ref15","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1158\/0008-5472.CAN-08-3863","article-title":"Prognostic Significance of Growth Kinetics in Newly Diagnosed Glioblastomas Revealed by Combining Serial Imaging with a Novel Biomathematical Model","volume":"69","author":"CH Wang","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.20946","article-title":"Prognostic value of initial magnetic resonance imaging growth rates for world health organization grade II gliomas","volume":"60","author":"J Pallud","year":"2006","journal-title":"Ann Neurol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1148\/radiol.2018171051","article-title":"Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma","volume":"288","author":"J P\u00e9rez-Beteta","year":"2018","journal-title":"Radiology"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.pharep.2017.03.008","article-title":"Temozolomide and sorafenib as programmed cell death inducers of human glioma cells","volume":"69","author":"J Jakubowicz-Gil","year":"2017","journal-title":"Pharmacol Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/0008-5472.CAN-04-2633","article-title":"Akt Activation Suppresses Chk2-Mediated, Methylating Agent Induced G2 Arrest and Protects from Temozolomide-Induced Mitotic Catastrophe and Cellular Senescence","volume":"65","author":"Y Hirose","year":"2005","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/cdd.2008.47","article-title":"Death through a tragedy: mitotic catastrophe","volume":"15","author":"H Vakifahmetoglu","year":"2008","journal-title":"Cell Death and Differ"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1201\/b15450","article-title":"Basic clinical radiobiology","author":"M Joiner","year":"2009"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ana.21125","article-title":"Dynamic history of low-grade gliomas before and after temozolomide treatment","volume":"61","author":"D Ricard","year":"2007","journal-title":"Ann Neurol"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","article-title":"The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation","volume":"15","author":"J Portnow","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ana.10528","article-title":"Continuous growth of mean tumor diameter in a subset of grade II gliomas","volume":"53","author":"E Mandonnet","year":"2003","journal-title":"Ann Neurol"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.biopsych.2007.03.001","article-title":"Evolving knowledge of sex differences in brain structure, function, and chemistry","volume":"62","author":"KP Cosgrove","year":"2007","journal-title":"Biol Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mbs.2017.02.003","article-title":"A mathematical model of low grade gliomas treated with temozolomide and its therapeutic implications","volume":"288","author":"MU Bogdanska","year":"2017","journal-title":"Mathematical Biosciences"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"e0178552","DOI":"10.1371\/journal.pone.0178552","article-title":"Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas","volume":"12","author":"A Henares-Molina","year":"2017","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/imammb\/dqv017","article-title":"Extreme protraction for low-grade gliomas: theoretical proof of concept of a novel therapeutical strategy","volume":"33","author":"VM P\u00e9rez-Garc\u00eda","year":"2016","journal-title":"Math Med Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1158\/1078-0432.CCR-12-0084","article-title":"A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy","volume":"15","author":"B Ribba","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/psp4.54","article-title":"Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics","volume":"4","author":"P Mazzoco","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref31","first-page":"297903","article-title":"Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation","volume":"2015","author":"P Mazzocco","year":"2015","journal-title":"Comp Math Meth in Medicine"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2184.2011.00790.x","article-title":"Improving the time-machine: estimating date of birth of grade II gliomas","volume":"45","author":"C Gerin","year":"2012","journal-title":"Cell Prolif"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/cpr.12114","article-title":"Oedema-based model for diffuse low-grade gliomas: application to clinical cases under radiotherapy","volume":"47","author":"M Badoual","year":"2014","journal-title":"Cell Prolif"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/imammb\/dqu009","article-title":"Delay effects in the response of low-grade gliomas to radiotherapy: A mathematical model and its therapeutical implications","volume":"32","author":"VM P\u00e9rez-Garc\u00eda","year":"2015","journal-title":"Math Med Biol"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/fcp.12259","article-title":"Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model","volume":"31","author":"E Ollier","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"e0179999","DOI":"10.1371\/journal.pone.0179999","article-title":"A Mathematical Model Describes the Malignant Transformation of Low Grade Gliomas: Prognostic implications","volume":"12","author":"MU Bogdanska","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"e1005977","DOI":"10.1371\/journal.pcbi.1005977","article-title":"Modeling the dynamics of oligodendrocyte precursor cells and the genesis of gliomas","volume":"14","author":"A Dufour","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"M Ramirez","year":"2016","journal-title":"Nat Commun"},{"issue":"21","key":"ref39","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1080\/15384101.2015.1090063","article-title":"The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma","volume":"14","author":"B Banelli","year":"2015","journal-title":"Cell Cycle"},{"key":"ref40","article-title":"Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma","author":"M Rab\u00e9","year":"2019","journal-title":"Journal of Biological Chemistry"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:03:45Z","timestamp":1588968225000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006778"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1006778","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/521559","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}